AR030019A1 - Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m - Google Patents

Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m

Info

Publication number
AR030019A1
AR030019A1 ARP000102352A ARP000102352A AR030019A1 AR 030019 A1 AR030019 A1 AR 030019A1 AR P000102352 A ARP000102352 A AR P000102352A AR P000102352 A ARP000102352 A AR P000102352A AR 030019 A1 AR030019 A1 AR 030019A1
Authority
AR
Argentina
Prior art keywords
monoclonal antibodies
human monoclonal
nucleic acid
pharmaceutical compositions
production
Prior art date
Application number
ARP000102352A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR030019A1 publication Critical patent/AR030019A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se refiere a nuevos anticuerpos monoclonales humanos (los mAb) y a los genes que codifican los mismos. Más específicamente, se refiere a anticuerpos monoclonales humanos específicamente reactivos con un epítope de la proteína de fusion (F) del virus sincitial respiratorio (RSV). Tales anticuerpos son utiles para el tratamiento terapéutico y/o profiláctico de la infeccion por RSV en pacientes humanos particularmente lactantes y ninos pequenos. Se describe además a un procedimiento para su produccion, composiciones farmacéuticas que los comprenden, una molécula de ácido nucleico aislada, un plásmido recombinante, una célula hospedante y el uso de dichos anticuerpos para la manufactura de un medicamento y para un agente de diagnostico.
ARP000102352A 1999-05-18 2000-05-16 Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m AR030019A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13470299P 1999-05-18 1999-05-18

Publications (1)

Publication Number Publication Date
AR030019A1 true AR030019A1 (es) 2003-08-13

Family

ID=22464579

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102352A AR030019A1 (es) 1999-05-18 2000-05-16 Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m

Country Status (6)

Country Link
EP (1) EP1178829A4 (es)
JP (1) JP2002543822A (es)
AR (1) AR030019A1 (es)
AU (1) AU5441000A (es)
CO (1) CO5280147A1 (es)
WO (1) WO2000069462A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004111233A1 (ja) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
WO2006106903A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2構造異性体
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US9241994B2 (en) 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
WO2006132352A1 (ja) * 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2を含有する医薬組成物
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
DK2285408T3 (en) 2008-06-05 2019-02-04 Ablynx Nv AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
HUE035773T2 (en) * 2009-06-05 2018-05-28 Ablynx Nv Trivalent human airway giant cell virus (hrsv) nanotubes for preventing and / or treating respiratory infections
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP2507262A1 (en) 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
SG11201602261VA (en) 2013-09-27 2016-04-28 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
JP7219005B2 (ja) 2015-12-28 2023-02-07 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
EP0671927B1 (en) * 1992-09-16 2003-01-15 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
CA2270288A1 (en) * 1996-11-01 1998-05-14 Smithkline Beecham Corporation Human monoclonal antibodies

Also Published As

Publication number Publication date
JP2002543822A (ja) 2002-12-24
CO5280147A1 (es) 2003-05-30
AU5441000A (en) 2000-12-05
EP1178829A4 (en) 2005-06-08
WO2000069462A1 (en) 2000-11-23
EP1178829A1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
AR030019A1 (es) Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m
ATE194291T1 (de) Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
JP2002544238A5 (es)
CN105566497A (zh) 融合铁蛋白在疫苗和其他方面的应用
ATE267258T1 (de) Impfstoffe für das respiratorische-synzytial- virus mit nuklein säuren
CA2181832A1 (en) Immunization by inoculation of dna transcription unit
WO2002072636A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
YU36302A (sh) Novi tiotropiumski preparati - koji sadrže prah za inhaliranje
BR9907691A (pt) Derivados de antìgeno associado a tumor da famìlia mage, e sequências de ácido nucléico codificando os mesmos, usados para a preparação de proteìnas de fusão e de composições para vacinação
JP2011521662A5 (es)
JP2004501618A5 (es)
JP2009520758A5 (es)
CN105106945B (zh) 一种幽门螺旋杆菌四价毒力因子多表位疫苗及其制备方法
CN107849551A (zh) 新型胰蛋白酶同功异型物和其用途
JPH05508847A (ja) 伝達因子および使用方法
HUP0401605A2 (hu) Szembetegségek kezelésére szolgáló integrin gátlók
WO2009079220A3 (en) Recombinant elastase proteins and methods of manufacturing and use thereof
WO2003079993A3 (en) hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION
CN111153988B (zh) 广谱抗肠道病毒d68型的中和性单克隆抗体
WO2004037175A3 (en) Compositions and methods for treating human papillomavirus-mediated disease
CN106606775A (zh) 脂质体a群链球菌疫苗
CN116406274A (zh) 用于治疗冠状病毒的cd3抗体
Shi et al. Expression, purification, and characterization of scar tissue neovasculature endothelial cell-targeted rhIL10 in Escherichia coli
EP0369816A3 (en) Monoclonal antibodies specific for human polymorphic epithelial mucin
BR9707142A (pt) Polinucleotìdeo purificado, dna, vetor, célula hospedeira, linhagem celular de hibridoma, anticorpo monoclonal, processos para produzir exodus, para aumentar a resistência à infecção por vìrus de imonudeficiência humana (hiv), para tratamento de infecção por vìrus de imonodeficiência humana (hiv), para proteção de células progenitoras de medula óssea contra os efeitos citotóxicos e para tratamento de doenças mieloproliferativas, e, uso de produto de proteina de exodus.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal